Compare · BDX vs CAH
BDX vs CAH
Side-by-side comparison of Becton Dickinson and Company (BDX) and Cardinal Health Inc. (CAH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BDX focuses on Medical/Dental Instruments, while CAH focuses on Other Pharmaceuticals.
- CAH is the larger of the two at $45.39B, about 1.1x BDX ($42.44B).
- Over the past year, BDX is down 12.1% and CAH is up 32.4% - CAH leads by 44.5 points.
- BDX has been more active in the news (15 items in the past 4 weeks vs 6 for CAH).
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- Cardinal Health Inc.
- Price
- $149.10+2.61%
- $192.88-4.85%
- Market cap
- $42.44B
- $45.39B
- 1M return
- -5.16%
- -8.75%
- 1Y return
- -12.07%
- +32.45%
- Industry
- Medical/Dental Instruments
- Other Pharmaceuticals
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 15
- 6
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Cardinal Health Inc.
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
Latest BDX
- BD Achieves Excellence in Employee Well‑Being, Earning Top Industry Recognition
- Becton Dickinson and Company filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- BD Reimagines Central Line Insertion, Advancing Leadership in Patient Safety Through Breakthrough Vascular Access Technology
- BD Board Declares Dividend
- EVP, Chief Revenue Officer Feld Michael sold $11,244 worth of shares (74 units at $151.94) as part of a pre-agreed trading plan, decreasing direct ownership by 0.35% to 21,159 units (SEC Form 4)
- BD to Present at Bank of America Securities Health Care Conference
- BD Earns Industry Top Honors for Transparency, Resiliency and Partnership
- Goldman resumed coverage on Becton Dickinson with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- BD to Announce Financial Results for its Second Quarter of Fiscal 2026
Latest CAH
- SEC Form 10-Q filed by Cardinal Health Inc.
- Cardinal Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises Outlook
- William Blair initiated coverage on Cardinal Health
- SEC Form 4 filed by Hall Patricia Hemingway
- Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings
- Cardinal Health expands Actinium-225 production capacity to support growing demand for novel cancer therapies
- Amendment: SEC Form SCHEDULE 13G/A filed by Cardinal Health Inc.
- Cardinal Health to Announce Third-Quarter Results for Fiscal Year 2026 on April 30
- Cardinal Health Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits